Anna Minchom News Today

Anna Minchom, MB BCh, MRCP, MD, discusses the need to develop an amivantamab administration method that decreases the likelihood of infusion-related reactions in patients with solid tumors, revealed the RP2D of subcutaneous amivantamab that was determined in the PALOMA trial, and emphasized potential future directions with this agent.

Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF)s cancer treatment has the capacity to ignite immunity in people with late-stage skin cancer where other...

A new study has shown that a new cancer treatment can stop the disease from advancing in patients who are out of options, which includes being resistant to immunotherapy. Some tumours can evolve to resist immunotherapy which uses the immune system to target and kill cancer cells. Combining immunotherapy with guadecitabine can reverse cancer’s resistance to the former, according to oncologists in the UK.

A new treatment may bring back hope for cancer patients who had become resistant to immunotherapy, a new ...

Exclusive: UK trial finds finds combination of drugs can work where tumours have become resistant to immunotherapy

A drug combination targeting multiple mutant versions of cancer’s ‘death star’ protein has shown promise in a small, early-phase clinical trial for some patients with advanced lung, ovarian and thyroid cancer. The two-drug combination was effective against advanced cancers with a range of mutations to the ...

/PRNewswire/ -- Faron Pharmaceuticals Ltd. ("Faron") Topline Biomarker Analysis Shows Bexmarilimab Ignites Immune Response in Patient Population That Has Not...

/PRNewswire/ -- Faron Pharmaceuticals Ltd. ("Faron") Topline Biomarker Analysis Shows Bexmarilimab Ignites Immune Response in Patient Population That Has Not...